Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060450 · ClinicalTrials.gov registry record · Phase 3
Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation
A Phase 3 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT00060450 is a Phase 3 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 84 participants.
The verdict
NCT00060450, a Phase 3 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of inhaled nitric oxide on both short-term physiology as well as on the development of ischemia-reperfusion lung injury (IRLI) in the immediate post transplant period. The specific hypothesis is that inhaled NO post lung transplantation will improve gas exchange/hemodynamic and thus reduce the development of post transplant IRLI.
Interventions
- DRUG Placebo
- DRUG nitric oxide for inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2001-08 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060450
The ClinicalTrials.gov registry entry for NCT00060450 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00060450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060450 about?
NCT00060450 is a clinical study titled "Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation". The purpose of this study is to evaluate the effects of inhaled nitric oxide on both short-term physiology as well as on the development of ischemia-reperfusion lung injury (IRLI) in the immediate post transplant period. The specific hypothesis is that inhaled NO post lung transplantation will impro...
What is the current status of trial NCT00060450?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2001-08. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00060450?
The interventions under investigation include: Placebo (DRUG), nitric oxide for inhalation (DRUG).
Who is sponsoring clinical trial NCT00060450?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.